Garry Walsh

Medicine & Life Sciences

1. Asthma 100%
2. Eosinophils 62%
3. Interleukin-5 49%
4. reslizumab 33%
5. Epithelial Cells 32%
6. Histamine Antagonists 32%
7. Biological Products 27%
8. Histamine H1 Receptors 25%
9. Cytokines 23%
10. Interleukin-4 20%
11. levocetirizine 20%
12. Therapeutics 19%
13. Anti-Inflammatory Agents 16%
14. Interleukin-13 16%
15. Chronic Obstructive Pulmonary Disease 16%
16. Cetirizine 15%
17. Biological Therapy 14%
18. Inflammation 14%
19. Nose 14%
20. Allergic Rhinitis 13%
21. montelukast 12%
22. Eosinophilic Esophagitis 12%
23. Monoclonal Antibodies 12%
24. Interleukin-8 11%
25. Chemokines 11%
26. pilsicainide 10%
27. mepolizumab 10%
28. Antibodies, Monoclonal, Humanized 10%
29. Newborn Infant 10%
30. Child 9%
31. Pyroglyphidae 9%
32. Interleukin-1 8%
33. Pediatrics 7%
34. Biomarkers 7%
35. Interleukin-6 7%
36. Leukotriene Antagonists 7%
37. Drug-Related Side Effects and Adverse Reactions 7%
38. Lung 7%
39. In Vitro Techniques 7%
40. Glucocorticoids 6%
41. Apoptosis 6%
42. Dyskinesias 6%
43. Parturition 6%
44. Environmental Exposure 6%
45. Antigen Presentation 6%
46. alcaftadine 6%
47. Vitamin E 6%
48. Helper-Inducer T-Lymphocytes 6%
49. Hypersensitivity 6%